MANY MINDEDHeart transplants show molecular age shifts toward recipients
Harvard Medical School researchers led by Vadim Gladyshev and Jesse Poganik published a preprint study showing heart transplants trigger epigenetic age shifts in human recipients. Analysis of 407 heart transplants (2002–2022) revealed transplanted hearts exhibited molecular age shifts toward the recipient’s chronological age: young donor hearts aged in older recipients, while older donor hearts rejuvenated in younger recipients. Native recipient organs showed no significant epigenetic age changes. The human findings relied on just 11 archived heart biopsies (5 from older donors, 6 from younger donors), with two of three methylation clocks demonstrating statistically significant age deviation differences between donor age groups.
The mechanism centers on epigenetic clocks — molecular markers that track biological age. Transplanted hearts appear to reset their molecular age toward the recipient’s biological timeline, potentially allowing older donors to be used in younger patients or enabling heart rejuvenation therapies for age-related heart failure.
This could expand organ donor eligibility and create pathways for heart rejuvenation treatments, addressing a critical need in heart failure care. However, the current findings do not yet translate to clinical applications. The small biopsy sample size and preprint status mean the results require validation through larger human studies and peer review before therapeutic implications can be realized.
What to watch: Peer review outcomes, expansion of human biopsy data, and whether epigenetic shifts translate to functional heart improvements in clinical practice. Caveats: Only 11 biopsies analyzed from 407 transplants; human findings based on limited molecular data; mouse experiments did not directly replicate human outcomes.
Source: Lifespan.io